

1 **Title: Investigating SARS-CoV-2 surface and air contamination in an acute healthcare**  
2 **setting during the peak of the COVID-19 pandemic in London**

3

4 **Authors:** Jie Zhou *research associate*,<sup>1\*</sup> Jonathan A. Otter *honorary senior lecturer*,<sup>2,3\*</sup>  
5 James R. Price *honorary senior lecturer*,<sup>2,3</sup> Cristina Cimpeanu *senior infection prevention*  
6 *and control nurse*,<sup>3</sup> Danel Meno Garcia *infection prevention and control nurses*,<sup>3</sup> James  
7 Kinross *clinical senior lecturer*,<sup>3,4</sup> Piers R Boshier *academic clinical fellow*,<sup>3,4</sup> Sam Mason  
8 *academic clinical fellow*,<sup>3,4</sup> Frances Bolt *research associate*,<sup>2,3</sup> Alison H. Holmes *professor of*  
9 *infectious diseases*,<sup>2,3</sup> Wendy S. Barclay *professor of virology*<sup>1</sup>

10

11 \* Joint first authors

12

13 **Affiliations:**

- 14 1. Department of Infectious Disease, Imperial College London, London, UK, W2 1PG.  
15 2. National Institute for Healthcare Research Health Protection Research Unit (NIHR  
16 HPRU) in HCAI and AMR, Imperial College London & Public Health England,  
17 Hammersmith Hospital, Du Cane Road, W12 0HS.  
18 3. Imperial College Healthcare NHS Trust, St. Mary's Hospital, Praed Street, London,  
19 W2 1NY, UK.  
20 4. Department of Surgery and Cancer, Imperial College London, London, UK, W2 1NY.

21

22

23 **Corresponding author:** Dr Jonathan Otter, Imperial College London, NIHR Health  
24 Protection Research Unit, Hammersmith Hospital, Du Cane Road, W12 0HS. Tel: 020 331  
25 33271, Email: [j.otter@imperial.ac.uk](mailto:j.otter@imperial.ac.uk).

26

27 **Key words:** SARS-CoV-2, COVID-19, decontamination, airborne transmission, droplet  
28 transmission, air contamination, surface contamination, disinfection

29 ***Role of the funding source***

30 National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in  
31 Healthcare Associated Infections and Antimicrobial Infections in partnership with Public  
32 Health England (PHE), in collaboration with, Imperial Healthcare Partners, University of  
33 Cambridge and University of Warwick supported this work. The views expressed in this  
34 publication are those of the author(s) and not necessarily those of the NHS, the National  
35 Institute for Health Research, the Department of Health and Social Care or Public Health  
36 England. Professor Alison Holmes is a National Institute for Health Research (NIHR) Senior  
37 Investigator. International Severe Acute Respiratory and Emerging Infection Consortium  
38 (ISARIC) provided funding for JZ and laboratory materials used for this study.

39

40 ***Author contributions***

41 All authors met the ICMJE criteria for authorship. JZ and JAO conceived the study, collected  
42 and analysed data, and wrote the manuscript; JRP conceived the study, collected data, and  
43 contributed to the manuscript; CP, DMG, PRB, SM collected data and contributed to the  
44 manuscript; FB, AHH, and ASB conceived the study, analysed data, and contributed to the  
45 manuscript. JAO is the study guarantor.

46

47 **ABSTRACT**

48

49 **Objectives:** To evaluate SARS-CoV-2 surface and air contamination during the peak of the  
50 COVID-19 pandemic in London.

51 **Design:** Prospective cross-sectional observational study.

52 **Setting:** An acute NHS healthcare provider.

53 **Participants:** All inpatient wards were fully occupied by patients with COVID-19 at the time  
54 of sampling.

55 **Interventions:** Air and surface samples were collected from a range of clinical areas and a  
56 public area of the hospital. An active air sampler was used to collect three or four 1.0 m<sup>3</sup> air

57 samples in each area. Surface samples were collected by swabbing approximately 25 cm<sup>2</sup> of  
58 items in the immediate vicinity of each air sample. SARS-CoV-2 was detected by RT-qPCR  
59 and viral culture using Vero E6 and Caco2 cells; additionally the limit of detection for  
60 culturing SARS-CoV-2 dried onto surfaces was determined.

61 **Main outcome measures:** SARS-CoV-2 detected by PCR or culture.

62 **Results:** Viral RNA was detected on 114/218 (52.3%) of surface and 14/31 (38.7%) air  
63 samples but no virus was cultured. The proportion of surface samples contaminated with  
64 viral RNA varied by item sampled and by clinical area. Viral RNA was detected on surfaces  
65 and in air in public areas of the hospital but was more likely to be found in areas immediately  
66 occupied by COVID-19 patients (67/105 (63.8%) in areas immediately occupied by COVID-  
67 19 patients vs. 29/64 (45.3%) in other areas (odds ratio 0.5, 95% confidence interval 0.2-0.9,  
68 p=0.025, Fisher's exact test). The PCR Ct value for all surface and air samples (>30)  
69 indicated a viral load that would not be culturable.

70 **Conclusions:** Our findings of extensive viral RNA contamination of surfaces and air across  
71 a range of acute healthcare settings in the absence of cultured virus underlines the potential  
72 risk from surface and air contamination in managing COVID-19, and the need for effective  
73 use of PPE, social distancing, and hand/surface hygiene.

74 **INTRODUCTION**

75

76 Since it was identified in Wuhan, China, in late 2019, the severe acute respiratory syndrome  
77 coronavirus (SARS-CoV-2) has rapidly spread around the world, resulting in a coronavirus  
78 disease 2019 (COVID-19) pandemic.<sup>1</sup> Experience from previous SARS and influenza  
79 outbreaks and emerging evidence for SARS-CoV-2 suggests droplet and contact spread as  
80 primary transmission routes.<sup>1 2</sup> Additionally, there is evidence that airborne spread can occur  
81 during aerosol generating procedures.<sup>1 2</sup>

82

83 In-hospital transmission to patients and healthcare workers was a key feature of SARS-CoV-  
84 1.<sup>1 3</sup> Hospital-onset COVID-19 infection has been reported, probably due to inadequate  
85 implementation of effective infection prevention and control measures.<sup>4</sup> The dynamics of  
86 transmission in the health care environment are unclear and likely to be multifactorial.  
87 Contaminated surfaces and air are recognised as a key part of the transmission dynamic of  
88 SARS, MERS, influenza, and other organisms in hospitals.<sup>1 2 5</sup> Laboratory evidence suggests  
89 that the SARS-CoV-2 virus can survive on dry surfaces and in aerosols for days to weeks,  
90 particularly on non-porous surfaces.<sup>6 7</sup> Furthermore, SARS-CoV-2 RNA has been detected  
91 on surfaces and in the air in hospitals that are caring for patients with COVID-19.<sup>8-13</sup>

92

93 However, our understanding of the role of surface and air contamination in the transmission  
94 of SARS-CoV-2 is limited. Most studies to date have relied on PCR to detect SARS-CoV-2  
95 on surfaces and in air, and have not attempted to culture live virus thereby limiting the ability  
96 to interpret the relevance of detection by PCR; all studies published so far have focussed  
97 upon one geographical region (Asia), and included a limited selection of clinical and non-  
98 clinical areas were included with no evidence from operating theatre environments.<sup>8 9 11 12</sup> In  
99 mid-April 2020, the UK was experiencing the first wave of the COVID-19 pandemic. During  
100 this period, there was evidence for hospital acquired infections with COVID-19.<sup>14</sup> Therefore,  
101 to inform and optimise infection prevention and control interventions, we evaluated surface

102 and air contamination across a range of clinically-relevant locations (including operating  
103 theatres) and public areas during the peak of the COVID-19 pandemic in London, using both  
104 RT-PCR and viral culture to detect SARS-CoV-2. We also performed supporting laboratory  
105 experiments to provide evidence on the viability of SARS-CoV-2 on surfaces, with  
106 associated limits of detection to qualify our findings.

107

## 108 **METHODS**

109

### 110 ***Setting***

111 Sample collection for this prospective cross-sectional study was performed between April 2<sup>nd</sup>  
112 and 20<sup>th</sup> 2020 on selected wards at a large North West London teaching hospital group  
113 comprising five hospitals across four sites with 1,200 acute beds, which prior to the  
114 pandemic undertook 1.2 million episodes of patient contact per year. Most sampling was  
115 conducted on one hospital site during the peak of the COVID-19 pandemic (Supplemental  
116 Figure 1) when most patients were managed in cohort wards.

117

### 118 ***Clinical areas selected for air and surface sampling***

119 Seven clinical areas and a public area of the hospital were selected to represent a range of  
120 clinical environments within our hospital group. These included:

- 121 • Adult emergency department, which included sections dedicated for suspected and  
122 confirmed COVID-19 patients (with 19 cubicles and a 6-bedded resuscitation bay)  
123 and for patients not suspected to have COVID-19 (with a two cubicle-bay, and two  
124 four-cubicle bays).
- 125 • A 16-bedded COVID-19 cohorting adult acute admissions unit with four four-bedded  
126 bay.
- 127 • A 32-bedded COVID-19 cohorting adult intensive care unit with four four-bedded  
128 bays and 16 single rooms.

- 129 • Theatres during tracheostomy procedures.
- 130 • Two adult COVID-19 cohort wards: one 20-bed ward with four four-bedded bays and  
131 four single rooms, and one 19-bed ward with a nine-bedded bay, an 8 bedded-bay  
132 and two single rooms.
- 133 • An adult ward area including a 6-bedded bay converted into a negative pressure  
134 area for management of continuous positive airway pressure (CPAP) on patients with  
135 COVID-19.
- 136 • The entrance and public area of the main hospital building.

137

138 All inpatient wards were fully occupied by patients with COVID-19 at the time of sampling,  
139 apart from the Emergency Department. In the part of the Emergency Department dedicated  
140 for patients with confirmed or suspected COVID-19, two of the cubicles were occupied and  
141 one patient was in the ambulatory wait area at the time of sampling. These areas were  
142 disinfected daily using a combined chlorine-based detergent/disinfectant (Actichlor Plus,  
143 Ecolab), with an additional twice daily disinfection of high touch surfaces using the same  
144 detergent/disinfectant.

145

146 In each of these clinical areas, four air samples were collected (five air samples were  
147 collected in the Emergency Department, and three in public areas of the hospital). Surfaces  
148 in the immediate vicinity of each air sample that were considered to be touched frequently by  
149 staff or patients were sampled. These included bed rails, clinical monitoring devices (blood  
150 pressure monitors), ward telephones, computer keyboards, clinical equipment (syringe  
151 pumps, urinary catheters), hand-cleaning facilities (hand washing basins, alcohol gel  
152 dispensers). In each clinical area, sampling was performed in both patient (i.e. bays and  
153 single rooms) and non-patient care areas (i.e. nursing stations and staff rooms).  
154 Environmental sampling was conducted during three tracheostomy procedures. During the

155 first procedure, air sampling was performed before and during the procedure; for the other  
156 procedures, air sampling was performed during the procedure only.

157

### 158 ***Sampling methods***

159 Air sampling was performed using a Coriolis  $\mu$  air sampler (referred to as Coriolis hereafter)  
160 (Bertin Technologies), which collects air at 100–300 litres per minute (LPM). After 10 min  
161 sampling at 100 LPM, a total of 1.0 m<sup>3</sup> air was sampled into a conical vial containing 5 mL  
162 Dulbeccos's minimal essential medium (DMEM). Surface samples were collected by  
163 swabbing approximately 25 cm<sup>2</sup> areas of each item using flocked swabs (Copan, US)  
164 moistened in DMEM. Temperature, humidity and time of day were recorded at the time of  
165 sampling. In all clinical settings, samples were taken in order from the lowest to highest  
166 perceived risk of SARS-CoV-2 contamination.

167

### 168 ***Detection and quantification of SARS-CoV-2 viral RNA genome and viral culture***

169 Viral RNA detection and absolute quantification was performed using quantitative real-time  
170 reverse transcription polymerase chain reaction (RT-qPCR). Samples were extracted from  
171 140  $\mu$ L of the DMEM medium using the QIAamp viral RNA mini Kit according to the  
172 manufacturer's instructions (Qiagen, Germany). Negative controls (water) were extracted  
173 and included in the PCR assays. SARS-CoV-2 viral RNA was detected using AgPath-ID  
174 One-Step RT-PCR Reagents (Life Technologies) with specific primers and probes targeting  
175 the envelop (E) gene.<sup>15</sup> The number of SARS-CoV-2 virus E gene copies per m<sup>3</sup> air and  
176 copies per swab were calculated. All samples were run in duplicate.

177

178 Viral culture: Vero E6 (African Green monkey kidney) and Caco2 (human colon carcinoma)  
179 cells were used to culture virus from air and environmental samples. The cells were cultured  
180 in DMEM supplemented with heat inactivated fetal bovine serum (10%) and  
181 Penicillin/Streptomycin (10, 000 IU/mL & 10, 000  $\mu$ g/mL). For propagation, 200  $\mu$ L of  
182 samples were added to 24 well plates. After 5-7 days, cell supernatants were collected, and

183 RT-qPCR to detect SARS-CoV-2 performed as described above. Samples with at least one  
184 log increase in copy numbers for the E gene (reduced Ct values relative to the original  
185 samples) after propagation in cells were considered positive by viral culture.

186

187 We defined samples where both of the PCRs performed from an air or surface sample  
188 detected SARS-CoV-2 RNA as positive, and samples where one of the two PCRs performed  
189 from an air or surface sample detected SARS-CoV-2 RNA as suspected.

190

191 We performed a laboratory experiment to determine the limit of detection for culturing SARS-  
192 CoV-2 dried on surfaces. A dilution series from solution containing  $8.25 \times 10^6$  PFU/mL SARS-  
193 CoV-2 (titred by plaque assay in Vero cells) from  $10^{-3}$  to  $10^{-6}$  (covering Ct values from 26 to  
194 36) was produced in DMEM and 50  $\mu$ L inoculated in triplicate onto the surface of plastic  
195 (standard keyboard key) or stainless steel (2 x 1 x 0.2 cm) pieces. The inoculated surfaces  
196 were dried in a safety cabinet for 2 hours after which they were visibly dry. They were then  
197 sampled using flocked swabs. Swabs were deposited into 1.5 mL of DMEM for 1 hour. RT-  
198 qPCR was used to determine viability following 7 days of culture as follows. 140  $\mu$ L was  
199 used for RNA extraction and qPCR immediately (0 days post inoculation, dpi) and after  
200 incubation for 7 days in a 24-well plate with VeroE6 cells (7 dpi). Samples with an increase  
201 in copy numbers for the E gene (reduced Ct values relative to the original samples) after  
202 propagation in Vero E6 cells were considered positive by viral culture.

203

#### 204 ***Statistical analysis***

205 A Fisher's exact test was used to compare the proportion of environmental samples  
206 (surfaces or air) that were positive or suspected for SARS-CoV-2 RNA in areas immediately  
207 occupied by patients with COVID-19 with other areas. The mean concentration of air and  
208 surface contamination in each of the areas was log transformed and then compared by one-  
209 way ANOVA followed by Tukey's multiple comparisons test.

210

211 ***Ethics approval***

212 The work was registered locally as an NHS service evaluation (#434).

213

214 **RESULTS**

215

216 114/218 (52.3%) of surface samples were suspected (91/218 (41.7%)) or positive (23/218  
217 (10.6%)) for SARS-CoV-2 RNA but no virus was cultured (Table 1). The proportion of  
218 surface samples contaminated varied by item, with suspected or positive RNA samples  
219 identified on >80% of computer keyboards/mice, alcohol gel dispensers, and chairs, and >50%  
220 of toilet seats, sink taps, and patient bedrails (Figure 1). A similar pattern was observed in air  
221 samples; no virus was cultured, but 14/31 (38.7%) of samples were suspected (12/31  
222 (38.7%)) or positive 92/31 (6.4%) for SARS-CoV-2 RNA (Table 1).

223

224 SARS-CoV-2 RNA was detected in air samples from all eight areas tested with levels  
225 ranging from  $10^1$  to  $10^3$  genome copies /  $m^3$  (Table 1); there was no significant difference in  
226 mean viral RNA concentration across the eight areas tested ( $p=0.826$ ). Similarly, SARS-  
227 CoV-2 RNA was detected in surface samples from all eight areas tested, with levels ranging  
228 from  $10^1$  to  $10^4$  copies per swab (Figure 2). There was a significant difference in the mean  
229 SARS-CoV-2 surface viral load across the eight areas tested ( $p=0.004$ ), with both Cohort  
230 Ward A and the Temporary CPAP ward showing higher levels of viral RNA; Cohort Ward A  
231 (mean =  $1.76 \log_{10}$  copies/swab) > Adult ICU (mean =  $0.0018 \log_{10}$  copies/swab) ( $p = 0.015$ ),  
232 and the Temporary CPAP Ward (mean =  $1.69 \log_{10}$  copies/swab) > Adult ICU ( $p = 0.016$ ).

233

234 Several clinical areas where AGPs are commonly performed were sampled. A suspected  
235 positive air sample was collected in the resuscitation bay in the emergency department,  
236 where aerosol generating procedures are commonly performed (although had not been  
237 performed for more than two hours prior to sample collection). In a ward temporarily  
238 converted for CPAP, SARS-CoV-2 RNA was detected from air within the negative pressure

239 CPAP bay, and outside the bay. No patient was undergoing CPAP at the time of sampling,  
240 but one patient was undergoing high-flow nasal cannula (HFNC) oxygen therapy. In the  
241 adult ICU, 3/4 air samples were suspected or positive. In operating theatres, 1/3 air samples  
242 collecting during three tracheostomy procedures was positive.

243

244 SARS-CoV-2 RNA was detected in surface and air samples in parts of the hospital hosting  
245 staff but not being used for direct patient care, including the staff room in the ICU, the  
246 nursing station outside of the CPAP unit, and in the hospital main entrance and public toilets.  
247 However, positive or suspected air and surface samples were significantly more likely to be  
248 found in areas immediately occupied by COVID-19 patients than in other areas (67/105  
249 (63.8%) in areas immediately occupied by COVID-19 patients vs. 29/64 (45.3%) in other  
250 areas (odds ratio 0.5, 95% confidence interval 0.2-0.9,  $p=0.025$ ).

251

252 Since viable virus was not cultured from any of the air or surface samples, we performed  
253 laboratory experiments to determine the limit of detection of SARS-CoV-2 dried onto  
254 surfaces. Viable SARS-CoV-2 virus could be cultured from experimentally contaminated  
255 dried surfaces with a Ct value  $<30$ ; this was consistent for plastic and metal test surfaces  
256 (Table 2). In our study, all surface and air samples from the hospital environment had a Ct  
257 value  $>30$ .

258

## 259 **DISCUSSION**

260

261 SARS-CoV-2 RNA was detected frequently from surface and air samples but we did not  
262 identify viable virus in any surface or air sample. Furthermore, our simulated laboratory  
263 studies showed that the RNA levels detected on environmental surfaces in the hospital were  
264 lower than the minimum that can be cultured from surfaces two hours after virus is  
265 deposited. SARS-CoV-2 RNA was identified across the eight areas that we tested, including  
266 areas of the hospital not used to care for patients with COVID-19 (e.g. public areas of the

267 hospital). However surface and air contamination was significantly more frequent in areas  
268 immediately occupied by COVID-19 patients than in other areas.

269

270 A direct comparison between our findings and other studies that have evaluated  
271 contamination of surfaces and air with SARS-CoV-2 is not possible due to differences in:  
272 environmental sampling strategy (including which clinical areas were included, which  
273 surfaces were sampled, and where air samples were collected from); experimental methods  
274 (including the method for sampling surfaces and the sampler used for air); the phase of the  
275 pandemic during which sampling was performed; the physical layout of buildings and clinical  
276 spaces (including the efficiency of air handling systems); individual patient characteristics  
277 including the stage and severity of disease and site of infection, which have been shown to  
278 influence shedding of SARS-CoV-2 and other hospital pathogens;<sup>4 16</sup> and the patient and  
279 staff testing, and cleaning and disinfection protocols. Nonetheless, our finding of widespread  
280 detection of viral RNA on surfaces (114/218, 52.3%) and to a lesser extent air (14/31,  
281 38.7%) is broadly consistent with the findings of most others although the proportion of  
282 surface and air samples positive for viral RNA is higher in our study.<sup>8-13</sup> For example, Ye et  
283 al. performed PCR detection of surface contamination in a range of clinical settings in a  
284 hospital caring for patients with COVID-19 in Wuhan, China.<sup>9</sup> Overall, 14% of 626 surface  
285 samples were positive for viral RNA, with a higher proportion of surface samples positive in  
286 the ICU (32% of 69 samples). However, other studies have identified very little or no  
287 contamination of surfaces or air.<sup>8 10</sup> Other studies have observed higher frequencies of  
288 contamination in patient-care vs. non-patient-care areas,<sup>8 9 11</sup> and variation in the frequency  
289 of contamination in across different clinical areas, which is in line with our findings.<sup>9 11</sup> One  
290 surprising finding in our study was that the level of contamination on surfaces in the ICU was  
291 lower than in a cohort general ward or in the temporary CPAP ward, in contrast to other  
292 findings.<sup>9</sup> This may be because most patients in the ICU are on closed ventilation systems,  
293 which may have a lower risk of producing surface and air contamination than some other  
294 settings.

295

296 We did not identify viable virus on any surface or air sample. To our knowledge, only one  
297 other study has attempted to culture SAR-CoV-2 from healthcare environments, and no  
298 viable virus was detected.<sup>10</sup> Our laboratory study of the viability of virus dried on surfaces  
299 helps to qualify our findings and the findings of others, suggesting that Ct values of >30 are  
300 unlikely to be culturable. Bearing in mind that the viral RNA detected in the hospital setting  
301 might have been deposited more than two hours previously, we cannot differentiate whether  
302 our inability to culture virus from the samples is explained by the low RNA levels or the  
303 length of time since deposition or both.

304

305 Surface contamination was detected on a range of items. Computer keyboards, chairs, and  
306 alcohol dispensers had the highest proportion of positive/suspected SAS-CoV-2 samples.  
307 Other studies have also identified computer keyboards and/or mice as a risk for  
308 contamination with SARS-CoV-2 RNA.<sup>8 9 11</sup> Many of the computers that we sampled were in  
309 shared staff clinical areas (such as nursing stations), so this argues for frequent disinfection  
310 of these items. The contamination of alcohol gel dispensers is unsurprising since staff hands  
311 activate these before hand hygiene is performed. However, alcohol gel dispensers should be  
312 included in routine cleaning and disinfection protocols.

313

314 We sampled several areas where aerosol generating procedures are commonly performed  
315 including the resuscitation bay in the emergency department, ICU, temporary CPAP ward,  
316 and operating theatres during tracheostomies. Positive or suspected air samples were  
317 identified in all of these clinical areas at a level of  $10^1$  to  $10^3$  copies /  $m^3$ . There was no  
318 difference in the viral load of the air across the eight areas sampled, which provides some  
319 evidence that AGPs do not produce persistently high levels of air contamination. However,  
320 we did not sample the air over time, and our air sampling method did not differentiate  
321 particle size so we are unable to distinguish droplets from aerosols (< 5  $\mu$ M). One recent  
322 study evaluated contamination of the air with SARS-CoV-2 in a permanent hospital and in a

323 field hospital in Wuhan, China.<sup>13</sup> Viral culture was not performed, but viral RNA was  
324 identified a low levels (in the  $10^1$ - $10^2$  range copies per  $m^3$ ) in patient care areas, and was not  
325 detected or detected in very low levels in public areas. Positive samples were identified in a  
326 range of particle sizes, including those  $<5 \mu M$ , which would typically be considered as  
327 aerosols.<sup>2</sup> It seems likely, therefore, that the positive and suspected air samples identified in  
328 our study included a range of particle sizes spanning  $5 \mu M$ , particularly in areas where  
329 aerosol generating procedures are common.

330

331 Whilst we performed sampling in a temporary CPAP ward, no patient was undergoing CPAP  
332 at the time of sampling. However, one patient was undergoing HFNC during the time of  
333 sample, and air contamination was identified  $<1 m$  from this patient. A recent summary of  
334 evidence concludes that HFNC is a lower risk procedure in terms of aerosol generation than  
335 CPAP, which should be a topic for future studies.<sup>17</sup>

336

337 We identified contamination of surfaces and air during three tracheostomy procedures.  
338 Several studies and commentaries have evaluated the potential for various surgical  
339 procedures to produce aerosols for patients with COVID-19.<sup>18-20</sup> One study evaluated the  
340 spread of droplets during tracheostomies, although did not include sampling for SARS-CoV-  
341 2.<sup>18</sup> Whilst our methods did not include measurement of particle size, our findings highlight a  
342 potential theoretical risk of transmission of COVID-19 during these procedures. However, a  
343 larger sample size is required to understand this risk

344

345 Our study has important strengths and limitations. Strengths include our sampling strategy  
346 encompassing contemporaneous surface and air samples from a range of clinical services  
347 including both patient care and non-patient care areas, specifically, we included operating  
348 theatres and areas dedicated to known and potential AGPs; each sample was tested using  
349 PCR and also viral culture, and we performed laboratory viral culture experiments to quality  
350 our findings; the sampling was conducted during the peak of the pandemic (and so likely

351 represents a worst-case scenario) in a European hospital group. Limitations include not  
352 collecting patient samples to better understand how our findings links to patient samples,  
353 particularly during tracheostomies and AGPs; no asymptomatic patient or staff testing  
354 ongoing at the time of sampling, which means patients and staff without known COVID-19  
355 could have been shedding SARS-CoV-2 and this would explain the detection of SARS-CoV-  
356 2 RNA in non-patient care areas; challenges in interpreting the significance of samples with  
357 low viral loads, ; a lack of resolution of particle sizes for contamination of the air; and no  
358 longitudinal sampling was performed so these findings represent a “snapshot”.

359

360 Our findings may have implications for future policy and guidelines. Most international  
361 guidelines recommend enhanced surfaces disinfection during the management of COVID-  
362 19. For example, Public Health England recommends enhanced disinfection using a  
363 chlorine-based disinfectant (or a disinfectant with effectiveness against coronaviruses). Our  
364 finding of widespread RNA contamination of clinical areas used to care for patients with  
365 COVID-19 supports the need for enhanced disinfection. Social distancing is recommended  
366 by most governments and personal protective equipment (PPE) is recommended during  
367 contact with patients with COVID-19 plus higher levels of PPE for performing aerosol  
368 generating procedures. Whilst we did not measure particle sizes during our air sampling, our  
369 findings highlight a potential role for contaminated air in the spread of COVID-19. Our finding  
370 of air contamination outside of clinical areas should be considered when making respiratory  
371 PPE recommendations in healthcare settings.<sup>21</sup>

372

373 Whilst SAR-CoV-2 RNA was detected within healthcare environments, further research  
374 linking patient, staff and environmental samples is required to better understand  
375 transmission routes. Longitudinal environmental and clinical sampling across healthcare  
376 settings is required to understand risk factors associated with viral shedding and  
377 transmission. Our findings can be used to parameterise mathematical models of COVID-19  
378 transmission. Finally, our methods can be used to assess the potential risk associated with

379 various procedures including some surgical and other procedures such as CPAP and  
380 nebulisation of medications. Findings from these studies may prompt changes to PPE  
381 recommendations for specific procedures, and the implementation of various innovative  
382 tools and approaches to reduce viral shedding (such as “helmet CPAP”).<sup>22-24</sup>

383

384 Whilst SARS-CoV-2 RNA was detected in clinical and non-clinical areas, no viable virus was  
385 recovered. These results are in line with other studies which have identified viral RNA but no  
386 viable SARS-CoV-2 within healthcare environments. Our findings of extensive viral RNA  
387 contamination of surfaces and air across a range of acute healthcare settings in the absence  
388 of cultured virus underlines the potential risk from surface and air contamination in managing  
389 COVID-19, and the need for effective use of PPE, social distancing, and hand/surface  
390 hygiene.

391

## 392 **ACKNOWLEDGEMENTS**

393 We wish to acknowledge the staff teams and patients who supported this sampling during  
394 the peak of the challenges posed by this pandemic.

395


**Table 1.** PCR results from surface and air samples.

		SURFACE SAMPLES							AIR SAMPLES		
		Total	positive	%positive	suspect	%suspect	positive or suspect	% positive or suspect	Result	Concentration (copies/m <sup>3</sup> )	Notes
<b>Cohort ward A</b>	Staff room	6	0	0.0	2	33.3	2	33.3	Negative		
	Nurse station	6	1	16.7	3	50.0	4	66.7	Negative		
	Toilet B (outside the patients' bay)	6	0	0.0	2	33.3	2	33.3	Negative		
	Cohort bay B	6	3	50.0	2	33.3	5	83.3	Positive	7048	
<b>Cohort ward B</b>	Staff room	4	0	0.0	0	0.0	0	0.0	Negative		
	Patients' toilet (in the ward)	7	0	0.0	1	14.3	1	14.3	Suspect	464	
	Male bay	12	1	8.3	4	33.3	5	41.7	Suspect	1335	
	Male bay (side room)	8	2	25.0	5	62.5	7	87.5	Suspect	163	
<b>Adult acute admission unit</b>	Ward managers office	5	1	20.0	2	40.0	3	60.0	Negative		
	Nurse station	7	0	0.0	5	71.4	5	71.4	Positive	404	
	Patient bay 2	8	0	0.0	2	25.0	2	25.0	Negative		
	Patient bay 1	10	0	0.0	8	80.0	8	80.0	Negative		
<b>Adult emergency department</b>	'Green' majors	10	1	10.0	5	50.0	6	60.0	Negative		
	Nurse station	4	2	50.0	0	0.0	2	50.0	Negative		
	Ambulatory waiting	3	2	66.7	1	33.3	3	100.0	Negative		
	Patient assessment cubicles	3	0	0.0	1	33.3	1	33.3			
	Male toilet (next to the nurse station)	2	0	0.0	1	50.0	1	50.0			
	Resus bay (last patient > 2 hours)	10	0	0.0	4	40.0	4	40.0	Suspect	35	
<b>Hospital public areas</b>	QEQM main entrance	7	1	14.3	4	57.1	5	71.4	Suspect	1574	
	Male toilet at QEQM main entrance	7	1	14.3	3	42.9	4	57.1	Suspect	1545	
	Lift area QEQM ground floor	10	0	0.0	4	40.0	4	40.0	Negative		
<b>Temporary CPAP ward</b>	Nurse station	5	1	20.0	2	40.0	3	60.0	Suspect	1922	
	CPAP unit	19	2	10.5	12	63.2	14	73.7	Suspect	31	< 1m from 2 patients
									Negative		> 2 m from patients
	PPE doffing area	5	0	0.0	2	40.0	2	40.0	Negative		
<b>Adult ICU</b>	Staff room	10	0	0.0	6	60.0	6	60.0	Suspect	249	
	Nurse station inside ICU	6	1	16.7	0	0.0	1	16.7	Negative		
	Bay area	11	0	0.0	5	45.5	5	45.5	Suspect	164	
	Side room bay area	8	2	25.0	4	50.0	6	75.0	Suspect	307	
<b>Theatres</b>	Theatres	13	2	15.4	1	7.7	3	23.1	Negative		Before tracheostomy
									Negative		During tracheostomy
									Suspect	1163	During tracheostomy
									Negative		During tracheostomy
	<b>Total</b>	<b>218</b>	<b>23</b>	<b>10.6</b>	<b>91</b>	<b>41.7</b>	<b>114</b>	<b>52.3</b>	<b>2/31 (6.4%) positive; 12/31 (38.7%) suspect</b>		


**Table 2:** Viability of SARS-CoV-2 dried onto steel or plastic surfaces from a dilution series; viability determined through RT-PCR from cultures immediately after drying, 0 days post inoculation (dpi) with Vero E6 cells compared with after culture (7 dpi). Means and standard deviations of Ct values are shown.

Inoculum (PFU)	Steel surface		Plastic surface	
	After drying (Ct)	After culture (Ct)	After drying (Ct)	After culture (Ct)
41.25	26.23 ± 0.30	12.65 ± 0.51 Pos	25.95 ± 0.06	11.16 ± 0.19 Pos
4.125	29.27 ± 0.04	12.86 ± 0.01 Pos	29.51 ± 0.29	12.58 ± 1.47 Pos
0.4125	32.54 ± 0.06	36.48 ± 1.80 Neg	32.67 ± 0.07	37.39 ± 0.21 Neg
0.04125	39.22 ± 5.13	41.33 ± 3.45 Neg	36.55 ± 0.23	39.76 ± 4.61 Neg


**Figure 1.** Proportion of environmental samples suspected or positive by item sampled. The number of the x axis represented the number of each item sampled.



**Figure 2.** SARS-CoV-19 E gene copy number from surface swabs. The quantity of E gene copy number per swab is shown. Suspect samples = blue dots; positive samples = red dots; negative samples = black dots.



**Supplemental Figure 1:** Trends in daily number of inpatients with COVID-19; the grey box indicates when surface and air samples were collected



## References

1. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? *Lancet Infect Dis* 2020;20(5):e102-e07. doi: 10.1016/s1473-3099(20)30129-8 [published Online First: 2020/03/09]
2. Otter JA, Donskey C, Yezli S, et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect* 2016;92(3):235-50. doi: 10.1016/j.jhin.2015.08.027 [published Online First: 2015/11/26]
3. Gowri G, Philip C, Yee Sin L, et al. SARS Transmission and Hospital Containment. *Emerg Infect Dis* 2004;10(3):395. doi: 10.3201/eid1003.030650
4. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Med* 2020;26(5):672-75. doi: 10.1038/s41591-020-0869-5 [published Online First: 2020/04/17]
5. Otter JA, Yezli S, Salkeld JA, et al. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. *Am J Infect Control* 2013;41(5 Suppl):S6-S11. doi: 10.1016/j.ajic.2012.12.004 [published Online First: 2013/05/03]
6. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New Engl J Med* 2020;382(16):1564-67. doi: 10.1056/NEJMc2004973 [published Online First: 2020/03/18]
7. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. *Lancet Microbe* 2020;1(1):e10. doi: [https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3)
8. Wu S, Wang Y, Jin X, et al. Environmental contamination by SARS-CoV-2 in a designated hospital for coronavirus disease 2019. *Am J Infect Control* 2020 doi: 10.1016/j.ajic.2020.05.003 [published Online First: 2020/05/15]

9. Ye G, Lin H, Chen S, et al. Environmental contamination of SARS-CoV-2 in healthcare premises. *J Infect* 2020 doi: 10.1016/j.jinf.2020.04.034 [published Online First: 2020/05/04]
10. Wang J, Feng H, Zhang S, et al. SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital. *Int J Infect Dis* 2020;94:103-06. doi: 10.1016/j.ijid.2020.04.024 [published Online First: 2020/04/21]
11. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerg Infect Dis* 2020;26(7) doi: 10.3201/eid2607.200885 [published Online First: 2020/04/11]
12. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *JAMA* 2020;323(16):1610-2. doi: 10.1001/jama.2020.3227 [published Online First: 2020/03/05]
13. Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* 2020 doi: 10.1038/s41586-020-2271-3 [published Online First: 2020/04/28]
14. Evans S, Agnew E, Vynnycky E, et al. The impact of testing and infection prevention and control strategies on within-hospital transmission dynamics of COVID-19 in English hospitals. *medRxiv* 2020:2020.05.12.20095562. doi: 10.1101/2020.05.12.20095562
15. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 2020;25(3) doi: 10.2807/1560-7917.es.2020.25.3.2000045 [published Online First: 2020/01/30]
16. Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the transmission of nosocomial pathogens. *Infect Control Hosp Epidemiol* 2011;32(7):687-99. doi: 10.1086/660363 [published Online First: 2011/06/15]

17. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. *Eur Resp J* 2020 doi: 10.1183/13993003.00892-2020 [published Online First: 2020/04/18]
18. Chow VLY, Chan JYW, Ho VWY, et al. Tracheostomy during COVID-19 pandemic-Novel approach. *Head Neck* 2020 doi: 10.1002/hed.26234 [published Online First: 2020/05/03]
19. Thamboo A, Lea J, Sommer DD, et al. Clinical evidence based review and recommendations of aerosol generating medical procedures in otolaryngology - head and neck surgery during the COVID-19 pandemic. *J Otolaryngol Head Neck Surg* 2020;49(1):28. doi: 10.1186/s40463-020-00425-6 [published Online First: 2020/05/08]
20. Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. *J Gastro Hepatol* 2020;35(5):749-59. doi: 10.1111/jgh.15053 [published Online First: 2020/04/02]
21. Garcia Godoy LR, Jones AE, Anderson TN, et al. Facial protection for healthcare workers during pandemics: a scoping review. *BMJ Global Health* 2020;5(5) doi: 10.1136/bmjgh-2020-002553 [published Online First: 2020/05/07]
22. Radovanovic D, Rizzi M, Pini S, et al. Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal. *J Clin Med* 2020;9(4) doi: 10.3390/jcm9041191 [published Online First: 2020/04/26]
23. David AP, Jiam NT, Reither JM, et al. Endoscopic Skull Base and Transoral Surgery During the COVID-19 Pandemic: Minimizing Droplet Spread with a Negative-Pressure Otolaryngology Viral Isolation Drape (NOVID). *Head Neck* 2020 doi: 10.1002/hed.26239 [published Online First: 2020/05/03]
24. Hirschmann MT, Hart A, Henckel J, et al. COVID-19 coronavirus: recommended personal protective equipment for the orthopaedic and trauma surgeon. *Knee Surg Sports Traumatol Arthrosc* 2020:1-9. doi: 10.1007/s00167-020-06022-4 [published Online First: 2020/04/29]

